Publications by authors named "P Ranalli"
Background: Serum thromboxane B (sTXB) is a validated biomarker of low-dose aspirin pharmacodynamics. In the original method, nonanticoagulated blood samples must be incubated at 37 °C immediately after withdrawal, centrifuged and serum supernatant should be frozen until assayed. Timely completion of all preanalytical steps may affect the feasibility and quality of sTXB measurements.
View Article and Find Full Text PDFNew available drugs allow better control of systemic symptoms associated with myelofibrosis (MF) and splenomegaly but they do not modify the natural history of progressive and poor prognosis disease. Thus, hematopoietic stem cell transplantation (HSCT) is still considered the only available curative treatment for patients with MF. Despite the increasing number of procedures worldwide in recent years, HSCT for MF patients remains challenging.
View Article and Find Full Text PDFArticle Synopsis
- People with essential thrombocythemia (ET) usually take low-dose aspirin once a day to avoid blood clots, but this isn't always effective because their platelet levels change quickly.
- A study tested if taking aspirin twice a day would work better and found that it did help lower certain blood markers and symptoms over 20 months.
- The results showed that twice-daily aspirin caused fewer major blood clots, didn't lead to significant bleeding problems, and made patients feel better overall compared to taking it once a day.